Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 317K | 2M |
| Gross Profit | -699K | 0 | 0 | 159K | 927K |
| Operating Income | -59M | -64M | -58M | -52M | -34M |
| EBITDA | -59M | -64M | -58M | -51M | -34M |
| Net Income | -56M | -61M | -53M | -51M | -34M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.51
-1.96% today
Window Change
-23.05%
Window
May 29, 2026 → Jun 22, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars · May 29, 2026 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Immuneering Corporation (IMRX) is a Healthcare stock with a market cap of $190.00M and listed on NASDAQ. The stock last traded around $4.51 and down 23.1% across the available one-year price window (May 29, 2026 → Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +37.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +37.7%, free cash flow +17.4% with operating margin 0.0% and ROIC -26.7%. Stock Foundry combines IMRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IMRX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IMRX Max Drawdown
-32.06%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for IMRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.1M
+556.2% YoY
FY Net Income
-$33.5M
+33.6% YoY
Free Cash Flow
-$30.9M
+31.1% YoY
Revenue Growth
+0.0%
EPS Growth
+37.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 317K | 2M |
| Gross Profit | -699K | 0 | 0 | 159K | 927K |
| Operating Income | -59M | -64M | -58M | -52M | -34M |
| EBITDA | -59M | -64M | -58M | -51M | -34M |
| Net Income | -56M | -61M | -53M | -51M | -34M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 129M | 36M | 59M | 73M | 75M |
| Total Assets | 232M | 53M | 103M | 122M | 167M |
| Total Liabilities | 14M | 11M | 12M | 13M | 11M |
| Shareholder Equity | 218M | 41M | 91M | 110M | 156M |
| Total Debt | 4M | 4M | 4M | 5M | 5M |
| Net Debt | -125M | -32M | -55M | -68M | -70M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
31M
+30.0% YoY
Capital Expenditures
61K
+91.8% YoY
Free Cash Flow
31M
+31.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-43.3%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.